Dutch Cohort Will Measure Whether Incretin Weight Loss Costs Muscle
A prospective Dutch study is aiming at a question now central to obesity care: when incretin therapy drives weight loss, how much of the drop comes from fat-free mass rather than fat alone? The IMPACT cohort will follow adults with overweight or obesity who either start or stop incretin treatment, with serial measurements designed to map the body composition of both weight loss and the weight regain that often follows treatment interruption.
The study is built around semaglutide and tirzepatide, two agents that have rapidly altered expectations for medical weight management. Their appetite-suppressing effects can produce substantial reductions in body weight, but clinicians have long recognized a quieter concern at the bedside: rapid weight loss does not always spare lean tissue. Skeletal muscle is not just an inert reservoir of protein. It supports mobility, metabolic health, and the physiologic reserve that protects older adults and patients with obesity from frailty, slowed gait, and loss of independence.
This cohort is designed to test that concern in real-world practice rather than in a tightly controlled drug trial. Investigators will enroll two groups: participants beginning incretin treatment and participants discontinuing it. Measurements are scheduled before the treatment decision, again at six months, and again at 12 months or when treatment ends or restarts. The structure creates a practical window into two distinct phases of obesity pharmacotherapy: active weight reduction and the rebound period after stopping therapy.
A single outcome sits at the center of the protocol: the ratio of fat-free mass to total weight loss during treatment, and the ratio of fat-free mass to recurrent weight gain after cessation. In plain clinical terms, the team is asking whether the body gives up mostly fat, mostly muscle, or a mixture of both when the scale moves. The same logic applies to rebound after treatment ends. If weight returns quickly, does lean tissue return with it, or does the patient regain predominantly adipose mass? Those are not academic distinctions for patients trying to preserve strength while losing weight.
Lean Mass, Strength, and Function Are Being Tracked Separately
The study does not stop at body composition. It also measures muscle strength and functional capacity, which are the outcomes that matter most to patients when they rise from a chair, climb stairs, or carry groceries. Maximal handgrip strength will be assessed with a dynamometer, and lower-extremity performance will be tested with an isometric leg extension protocol. Functional capacity will be captured with the Four Metre Walk Test and the Timed Chair-Stand test.
Those measures are clinically important because lean tissue and physical performance do not always move in parallel. A person may lose a modest amount of fat-free mass without a large immediate drop in strength, particularly if activity levels stay high or protein intake remains adequate. The opposite can also happen: a patient may preserve measured muscle mass yet still slow down, especially if weight loss is accompanied by undernutrition, fatigue, or reduced resistance training. By collecting both structural and performance data, the cohort can show whether body composition changes translate into bedside consequences.
The protocol also includes objective physical activity monitoring with an activity monitor, along with questionnaires on health status, incretin treatment, diet, and activity habits. A validated food frequency questionnaire will estimate habitual protein intake, and a muscle-strengthening exercise questionnaire will assess resistance training behavior. Those details matter because muscle outcomes in obesity treatment are shaped by more than medication alone. Energy deficit, protein consumption, and exercise exposure all influence whether weight loss is metabolically healthy or comes with unnecessary loss of lean tissue.
Blood sampling adds another layer of context. Non-fasted venous blood will be used to assess HbA1c, lipids, high-sensitivity C-reactive protein, and creatine kinase. Incretin therapy often improves glycemic control and cardiometabolic risk markers, but muscle complaints, reduced intake, or training changes can affect creatine kinase and performance. The biomarker panel should help place body composition shifts alongside broader metabolic change.
Weight Regain After Stopping Therapy Is Part of the Question
The inclusion of a discontinuation cohort gives the study uncommon relevance. In clinical practice, many patients do not remain on anti-obesity medication indefinitely, and treatment interruption is often followed by weight regain. What is less certain is whether the returning kilograms are distributed across fat and fat-free mass in the same way as the original weight loss. If lean tissue is preferentially lost during treatment and not fully restored afterward, the long-term implications for mobility and metabolic health become more serious than a simple weight chart suggests.
The study design should also help distinguish temporary pharmacologic effects from longer biological adaptations. Appetite suppression can reduce overall caloric intake, but if protein intake falls too far or physical activity declines, muscle loss may accelerate. Conversely, if the cohort maintains activity and resistance training, lean mass preservation may be better than feared. Real-world observational follow-up is well suited to capture those variable patterns because it reflects what happens in routine obesity care rather than under idealized trial conditions.
This is not a medication efficacy study in the traditional sense. No treatment will be assigned by the investigators, and participants will receive incretin therapy as part of usual care. The value lies in characterization: understanding what happens to the body during treatment, and what happens again when treatment stops. That distinction is especially relevant for patients who have struggled with repeated cycles of weight loss and regain.
Why the Cohort Could Influence Obesity Counseling
For clinicians, the most useful result from a study like this may not be a single headline number. It may be the ability to counsel patients more precisely about expected body composition changes, to decide when protein intake deserves more attention, and to reinforce resistance training when lean mass preservation becomes a priority. A patient starting semaglutide or tirzepatide may care about the scale first, but preserving strength often determines whether the weight loss feels beneficial or physically costly.
The cohort plans to enroll about 200 participants and follow them for up to two years, with a target follow-up duration of two years. Adults 18 years and older with overweight or obesity are eligible if they are starting incretin therapy or planning to discontinue it, while prior bariatric or endoscopic obesity procedures and prior incretin or other obesity medication use are exclusion criteria. The study is being conducted at Radboud University Medical Center with collaboration from ZonMw, the Netherlands Organisation for Health Research and Development.
A practical question sits beneath the protocol: can obesity pharmacotherapy produce weight loss without paying an unnecessary muscle penalty? This study is structured to answer it with direct measurement rather than assumption. If the balance between fat loss, lean tissue loss, strength, and function shifts in either direction, that will matter for how incretin therapy is framed in day-to-day obesity care.
The remaining uncertainty is not whether these drugs work for weight loss; that part is already clear. The unresolved issue is how the lost weight is partitioned, and what happens to muscle and function when treatment continues or ends. The IMPACT cohort is built to follow those consequences where patients feel them most: in their legs, their grip, their gait, and their ability to keep moving.